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BACKGROUND/OBJECTIVES: Our objective was to investigate effects of an oral nutritional supplement containing n-3
polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with
non-small cell lung cancer (NSCLC) undergoing multimodality treatment.
SUBJECTS/METHODS: In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of
a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02g eicosapentaenoic
acidþ0.92g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life,
Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of
intervention were analysed by generalised estimating equations. P-values o0.05 were regarded as statistically signiﬁcant.
RESULTS: The intervention group reported signiﬁcantly higher on the quality of life parameters, physical and cognitive function
(B¼11.6 and B¼20.7, Po0.01), global health status (B¼12.2, P¼0.04) and social function (B¼22.1, P¼0.04) than the control
group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B¼5.3, P¼0.04) than the control
group after 3 weeks. Handgrip strength did not signiﬁcantly differ between groups over time. The intervention group tended to
have a higher physical activity than the control group after 3 and 5 weeks (B¼6.6, P¼0.04 and B¼2.5, P¼0.05).
CONCLUSION: n-3 Polyunsaturated FAs may beneﬁcially affect quality of life, performance status and physical activity in
patients with NSCLC undergoing multimodality treatment.
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INTRODUCTION
Lung cancer is a leading cause of cancer death worldwide, causing
approximately 1.2 million deaths per year.
1 The two major types of
lung cancer are non-small cell lung cancer (NSCLC) and small cell
lung cancer, differentiated by cell type and biological behaviour.
NSCLC accounts for 85% of all lung cancers.
2
Stage IV NSCLC has the shortest survival and is merely treated
by palliative chemotherapy. Patients with localised or locoregional
disease, such as stage III NSCLC, receive multimodality treatment
with curative intent.
This multimodality treatment includes concurrent chemo-
radiotherapy, followed by surgery.
3- -5
Concurrent chemoradiotherapy increases the length and
potential toxic effects of treatment as well as the rehabilitation
and recovery process. This treatment frequently extends
to 2 months, and the combined side effects can affect all areas
of functioning, such as physical, psychosocial and nutritional
status.
3
Yet, little is known about physical, psychosocial and nutritional
status in lung cancer patients undergoing multimodality treat-
ment. Anorexia and weight loss are frequently observed, which
affects nutritional status and in turn might have an impact on the
treatment toxicity, quality of life and survival.
6- -9
Nutritional therapy in cancer patients aims to maintain or
improve nutritional status and quality of life during cancer
therapy, and to improve tolerance to treatment,
9 but an increase
of energy and nutrient intake in cancer has shown to be
ineffective because of tumour-derived catabolism.
9- -11
Research currently focuses on therapeutic agents, which
modulate catabolism and appetite, for instance pharmaconutri-
ents that are able to inhibit protein degradation and to stimulate
protein synthesis.
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www.nature.com/ejcnIn this respect, n-3 polyunsaturated fatty acids (FAs) from ﬁsh oil
have presumable immune-modulating effects, partly caused by
the formation of 3- and 5-series inﬂammatory mediators with a
lower proinﬂammatory and immunosuppressive effect.
12,13 In
particular, eicosapentaenoic acid (EPA) has been shown to reduce
the production of inﬂammatory cytokines and to treat tissue
wasting in patients with cancer.
12,13 Apart from immune-
modulating effects of n-3 FAs and indications of preservation of
body weight,
14,15 one small trial documented an improved
physical activity in a small group of patients with pancreatic
cancer.
16
Up to now, a few randomised controlled trials showed
promising effects of n-3 polyunsaturated FAs on quality of life
and functional status in cancer patients receiving palliative care,
without assessing physical activity.
17,18
The aim of this paper was to investigate the effects of a
nutritional supplement containing n-3 polyunsaturated FAs on
quality of life and functional status (performance status, handgrip
strength and physical activity) in patients with stage III NSCLC
undergoing multimodality treatment.
SUBJECTS AND METHODS
Patients
We included 42 patients with histological or cytological proven stage IIIa-
N2 or IIIb NSCLC. Patients 18- -80 years of age were included if they were
eligible for multimodality treatment, and if their life expectancy was 43
months. Patients who had undergone surgery, chemotherapy or radio-
therapy during the previous month and patients with oedema, ascites,
severe comorbidities, or using high-dose corticosteroids or ﬁsh oil
supplements during the previous month were excluded.
Multimodality consisted of concurrent chemoradiotherapy; for the
description of the treatment schedule, we refer to our previous publication.
Study design
This study is set up as a randomised, double-blind, placebo-controlled trial.
We prescribed two packages per day of either a protein- and energy-dense
oral nutritional supplement containing n-3 polyunsaturated FAs (ProSure,
Intervention) or an isocaloric control oral nutritional supplement (Ensure,
Control) during 5 weeks of chemoradiotherapy. Details on the oral
nutritional supplements that are displayed have been previously
described.
19 The Medical Ethics Committee of the VU University Medical
Center Amsterdam approved the trial and all patients provided written
informed consent.
We continuously monitored compliance with the study supplements
and adverse events. We assessed quality of life, Karnofsky Performance
Status and physical activity at baseline, after 3 and 5 weeks. Patients
performed handgrip strength tests at baseline and every week for 5 weeks.
Random assignment
The pharmacist randomised patients, stratiﬁed by chemotherapy schedule,
in blocks of four to the intervention (I) group (n¼20) or control (C) group
(n¼20). Independent employees prepared numbered batches of study
supplements in the pharmacy. After inclusion of a patient, the pharmacist
assigned a batch number. This batch was delivered to the patient
concerned. Patients, investigators and study personnel were blind to the
treatment group allocation.
19
Compliance with study supplements
We used two methods to evaluate compliance with study supplements.
First, patients were instructed to record supplement intake in a compliance
diary. Second, plasma phospholipids EPA levels were assessed at baseline
and after 5 weeks, as an objective indicator of study supplement intake, as
described previously.
19
Quality of life
Patients ﬁlled out a self-administered questionnaire, the EORTC-QLQC30, a
multidimensional validated cancer-speciﬁc measure that includes global
health status and quality of life, functional and symptom scales.
20
Global health status implies the patient’s own judgment of health
status and quality of life. Physical function score expresses the capacity to
perform normal daily activities. Other functional scales include role
function (the capacity to perform work, daily activities, hobbies or other
leisure activities), cognitive function, and emotional and social function.
EORTC-QLQC30 subscales were calculated according to the EORTC-
QLQC30 manual and vary from 0 to 100. A high score for a functional or
quality of life scale represents a high level of functioning or quality of life. A
high score for a symptom scale represents a high level of problems.
The investigator recorded the Karnofsky Performance Status, a valid and
widely used instrument to quantify the functional status of cancer patients.
The Karnofsky Performance Status ranges from 0 to 100, with a higher
score indicating a better ability to carry out normal daily activities and
work.
21,22
Handgrip strength
Handgrip strength was measured in the nondominant hand using a
hydraulic hand dynamometer (Baseline; Fabrication Enterprises, White
Plains, NY, USA). The patient performed the test in sitting position, with the
shoulder adducted and neutrally rotated, elbow ﬂexed at 901, forearm and
wrist in neutral position. Patients were instructed to perform two maximal
isometric contractions. Patients took brief pauses between measurements.
The maximal value was recorded to the nearest 0.5kg, and the mean of
two measurements was used to compare with age- and sex-dependent
reference values for handgrip strength.
23 If patients were unable to
perform handgrip strength with their nondominant hand, handgrip
strength of the dominant hand was measured.
Through the entire study period, measurements were performed with
the same hand.
Physical activity
Physical activity in daily life, assessed by accelerations of the hip, was
measured with the physical activity monitor (PAM) accelerometer (model
AM101, 28190g, 59 43 10mm
3; PAM B.V., Doorwerth, The Netherlands).
The PAM produces a single index score on its display, which
accumulates during the day and is a proxy measure of total daily physical
activity. Every 3 points of the physical activity score reﬂects about 10min of
walking.
24 Moreover, the PAM has the ability to register minutes of low and
moderate intensity physical activity. Low intensity physical activity
corresponded with small in-house movements; moderate intensity
corresponded with walking.
25 The reliability and validity of the PAM
accelerometer has been tested in a laboratory setting and has shown
results similar to the MTI Actigraph for estimating energy expenditure in
walking and stair walking.
The PAM was calibrated on a shaking device (2.1kHz) prior to the study.
Patients were instructed to wear the PAM for 7 consecutive days at the
following time points: after inclusion (before starting with study
supplements) and during the third and ﬁfth week of the study. PAM data
were included if the PAM was worn during at least 3 full days during the
week before admission to the hospital; average daily PAM scores and
minutes of low and moderate intensity were calculated.
Adherence to chemoradiotherapy protocols
The investigator registered acute, nonscheduled hospital admissions,
adherence to chemoradiotherapy protocols and chemotherapy delay,
using medical records from the departments of pulmonary diseases and
radiation oncology.
Statistics
The primary end point of this study and the sample size calculation on
body weight have been described previously.
19 The statistical power of
remaining parameters was calculated by entering the expected sample
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5 weeks. With a signiﬁcance level of 0.05, the statistical power of quality
of life parameters was 66% (global health status) and 97% (physical
function), respectively , and the statistical power of Karnofsky Performance
Status, hand grip strength and physical activity were 51, 25 and 55,
respectively.
Differences between groups for patient characteristics at baseline for
nominal and ordinal variables were analysed by w
2 tests. For continuous
variables, differences between groups at baseline were analysed by linear
regression analysis with sex as covariate.
The primary analysis of the effect of n-3 FAs was performed on an
intention-to- treat basis of all patients as randomised and allocated to the I
or C group.
Generalised estimating equation, a longitudinal linear regression
technique, to account for the dependency of the observations in time,
was used to analyse the effects of intervention over time for continuous
variables. Adjustments were made by addition of baseline values and sex
as covariates. Independent dummy variables for group (I or C group) and
for separate time points (week 1, 2, 3, 4 and 5) were entered into the
generalised estimating equation model. Absolute differences between I
and C groups were expressed as B. The generalised estimating equation
method is suitable for designs with unequally spaced time intervals.
26,27
We used an exchangeable correlation structure to analyse the data, using
SPSS 16.0 (SPSS Inc., Chicago, IL, USA). The exchangeable correlation
structure assumes the correlation within different time points and is equal
for all time points.
28 P-values o0.05 were considered as statistically
signiﬁcant.
RESULTS
We included 40 eligible patients with stage III NSCLC, 21 men and
19 women, with median age 57.8 years (range 39--80). In all, 16
patients had stage IIIa NSCLC and 24 patients had stage IIIb
NSCLC.
The I group consisted of more men than the C group
(P¼0.001). Other baseline characteristics did not differ between
the I and C groups. Quality of life variables did not differ between
groups at baseline after adjustment for sex (Table 1).
We assessed 40 patients (I: n¼20, C: n¼20) at baseline,
35 patients (I: n¼15, C: n¼20) after 3 weeks and 33 patients
(I: n¼14, C: n¼19) after 5 weeks. Five patients of the I group
dropped out within 3 weeks. Reasons for dropout were with-
drawal of consent (n¼3), disease progression (n¼1) or the
occurrence of an adverse event. Compared with patients who did
not drop out within 3 weeks, those ﬁve patients had a comparable
Karnofsky Performance Status, global health status, physical
function and stage of disease at baseline.
Compliance with study supplements
Consumption of study supplements during chemoradiotherapy
was approximately one package a day in both the I and C groups
(P40.05). After 5 weeks, plasma phospholipid concentrations of
EPA and docosahexaenoic acid of the I group were signiﬁcantly
higher than those of the C group. For detailed results on
compliance, we refer to our previous publication.
19
Quality of life
Patients in the I group performed in general better on quality of
life scores than patients in the C group (Table 2). After 3 weeks, the
I group had a higher Karnofsky Performance Status (B¼5.3,
P¼0.04) than the C group. After 5 weeks, Karnofsky Performance
Status did not differ between groups.
After 5 weeks, the I group showed a signiﬁcantly better global
health status (B¼12.2, P¼0.04), physical function (B¼11.6,
Po0.01), cognitive function (B¼20.7, Po0.01) and social function
(B¼22.1, P¼0.04) on the EORTC-QLQC30 subscales than the
C group. In addition, the I group reported less nausea/vomiting
(B¼ 16.0, P¼0.04) and less ﬁnancial problems (B¼ 9.5,
P¼0.04) than the C group after 5 weeks. Other functional or
symptom scales of the EORTC-QLQC30 did not signiﬁcantly differ
between groups at any time point.
Physical activity level
Physical activity scores of patients are depicted in Table 2 and
Figure 1. Mean daily physical activity score in the patient population
amounted 6.3, which is considerably lower than in healthy people
(approximately 20).
24 In both groups, at least two-thirds of patients
were able to wear the PAM accelerometer, during 5.4±2.4 days at
baseline, 5.9±2.2 days during week 3 and 7±3.3 days during week
5, with no signiﬁcant differences between the I and C groups. Most
often mentioned reasons for not wearing the PAM were forgetful-
ness, taking the PAM off when taking a short bed rest and difﬁculties
with wearing a visible device.
During week 3 and 5, the I group tended to have a considerably
higher daily physical activity score (B¼6.6, P¼0.04 and B¼2.5,
P¼0.05, respectively). There were no differences between the I
and C groups in minutes of low and moderate intensity activity
during week 3 and 5 (Table 2).
Table 1. General and baseline characteristics of 40 patients with stage
III NSCLC
I( n¼20) C (n¼20) P
a
Sex (F), n (%) 4 (20%) 15 (75%) o0.01*
Age (years) 58.4±12.0 57.2±8.1 0.59
Stage of disease, n (%) 0.42
IIIa 9 (45%) 7 (35%)
IIIb 11 (55%) 13 (65%)
Nutritional status
BMI (kg/m
2) 24.8±4.1 23.0±2.4 0.42
Weight loss in the previous
month (%)
 0.3±2.4  1.5±4.7 0.56
Body weight (kg) 77.1±14.6 64.7±7.4 0.12
Handgrip strength (kg) 31.3±9.8 26.1±7.8 0.29
Karnofsky performance status 84.0±11.4 80.5±10.0 0.84
60 1 (5%) 0 (0%)
70 4 (20%) 8 (40%)
80 4 (20%) 4 (20%)
90 8 (40%) 7 (35%)
100 3 (15%) 1 (5%)
EORTC QLQC30
Global health status 60.2±24.7 53.8±21.7 0.81
Functional scales
Physical function 73.6±20.2 68.3±20.8 0.78
Role function 50.9±39.0 50.0±63.3 0.97
Emotional function 70.6±21.8 64.3±29.9 0.73
Cognitive function 81.6±14.6 71.7±26.0 0.75
Social function 63.9±30.4 55.8±28.8 0.59
Physical activity
a
Day score (PAM activity score) 7.2±8.7 5.7±5.0 0.84
Low-intensity physical
activity (min/day)
46.5±51.5 45.8±27.7 0.73
Moderate-intensity physical
activity (min/day)
48.0±67.9 31.0±33.2 0.60
Abbreviations: BMI, body mass index; C, control; EORTC-QLQ, European
Organisation for Research and Treatment of Cancer-Quality of Life
Questionnaire; I, intervention; NSCLC, non-small cell lung cancer. Results
are presented as mean±s.d., unless stated otherwise.
aP-value of
difference between groups, with sex included as covariate in the
regression model. *Po0.01.
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At baseline, handgrip strength of the study population was on
average 92.2±21.2% of age- and sex-speciﬁc reference values and
not signiﬁcantly different between the I and C groups. Over time,
handgrip strength did not signiﬁcantly differ between the groups
(Table 2).
Adherence to chemoradiotherapy protocols
The number of patients with chemotherapy delays was four in the
I group and two in the C group (P¼0.48). One patient in the C
group needed a chemotherapy dose reduction. The number of
patients with nonscheduled hospital admissions was 9 in the I
group and 10 in the C group (P¼0.87). There were some patients
who needed more than one nonscheduled hospital admission
(I: n¼1: 3, C: n¼1: 2, n¼1: 3).
In both groups, there were various reasons for hospital
admission, most often fever or nausea, vomiting and dehydration
after chemotherapy. Other reasons were disease progression,
pneumothorax, PEG-tube placement, depression, thrombosis and
overall malaise.
DISCUSSION
This randomised controlled trial investigated effects of an oral
nutritional supplement containing n-3 FAs on quality of life and
functional status in patients with NSCLC during multimodality
treatment. Observed differences between intervention and
placebo groups suggest some beneﬁcial effects of the oral
nutritional supplement containing n-3 polyunsaturated FAs on
quality of life and physical activity. These ﬁndings correspond with
positive effects of n-3 FAs on nutritional status in the same patient
population.
19
FAs are important constituents of immune cell membranes and
precursors of prostanoids and leukotrienes. In contrast to n-6 FAs,
n-3 FAs downregulate the production of pro-inﬂammatory
cytokine production and cachectic factors. As a result, n-3 FAs
might reduce anorexia, REE, muscle degradation and weight loss
in cancer patients.
29- -32 Maintenance of body weight and fat-free
mass is expected to improve quality of life.
9
Previous studies showed malnutrition to be associated with a
reduced quality of life in patients with head and neck
8,33 and
colorectal cancer,
34 and in patients with radiotherapy for different
types of cancer.
35 Lung cancer patients with weight loss showed
more symptoms, chemotherapy delay, anaemia and fewer
symptomatic responses to chemotherapy than those without
weight loss.
6 Ravasco et al.
8 were the ﬁrst to show beneﬁcial
effects of nutritional counselling on nutritional status, quality of
life and outcome in head and neck cancer patients during
radiotherapy.
To achieve immune modulation and effects on nutritional status
and quality of life, patients’ compliance with n-3 FA supplementa-
tion is essential. Plasma phospholipids’ EPA levels and compliance
diaries showed that the overall compliance with the study oral
nutritional supplements was lower than expected. There was no
signiﬁcant difference between the I and C groups in the number
of study supplements consumed, despite the lower prevalence of
nausea and vomiting in the intervention group. Causes for
suboptimal compliance of the study supplements, as mentioned
by patients of both the I and C groups, were anorexia, palatability
and early satiety, and patients’ preference to consume normal oral
food rather than oral nutritional supplements. As suboptimal
compliance with n-3 FA supplements has been reported in other
studies, this conﬁrms the need to develop more feasible methods
of n-3 FA supplementation for cancer patients, either or not
combined with other methods to enhance energy and protein
intake.
In addition, some patients showed increased plasma phospho-
lipids’ EPA levels at baseline. A number of control patients
showed high levels after 5 weeks, indicating abnormal n-3
FA intake from ﬁsh or ﬁsh oil capsules. As a result, we might
Table 2. Quality of life, physical activity and handgrip strength after 3
and 5 weeks for the I and C groups with stage III NSCLC
Week 3 Week 5
B P B P
EORTC QLQC30
Global health status 0.4 0.95 12.2 0.04*
Functional scales
Physical function  1.7 0.76 11.6 o0.01*
Role function  14.9 0.21 17.0 0.13
Cognitive function  0.1 0.99 20.7 o0.01*
Emotional function  8.6 0.25 6.8 0.30
Social function 2.0 0.87 22.1 0.04*
Symptom scales
Fatigue 4.8 0.57 0.5 0.95
Pain 2.4 0.79  2.7 0.79
Nausea/vomiting  9.9 0.06  16.0 0.04*
Dyspnoea  10.4 0.12  8.7 0.46
Loss of appetite  5.0 0.64  2.6 0.82
Insomnia 16.1 0.16 13.0 0.33
Constipation  1.4 0.86 6.2 0.64
Diarrhoea  5.2 0.62 1.2 0.90
Financial problems  6.0 0.29  9.5 0.04*
Karnofsky performance status 5.3 0.04* 7.2 0.10
Physical activity
a
Day score (PAM activity score) 6.6 0.04* 2.5 0.05
Low-intensity physical activity
(min/day)
19.4 0.52  4.0 0.85
Moderate-intensity physical
activity (min/day)
26.0 0.26 4.9 0.64
Hand grip strength (kg)
b 1.8 0.15 1.8 0.25
Abbreviations: B, difference between I and C groups (analysed by
generalised estimating equations, corrected for baseline value and sex),
B40 implies a higher change in the I group than the C group; C, control;
EORTC-QLQ, European Organisation for Research and Treatment of Cancer-
Quality of Life Questionnaire; I, intervention.
aWeek 3: n¼13 (I) and n¼17
(C), week 5: n¼8 (I) and n¼13 (C).
bWeek 3: n¼12 (I) and n¼16 (C), week
5: n¼10 (I) and n¼16 (C). *Po0.05.
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Figure 1. Physical activity (daily PAM score) over time for the I and C
groups. Values are mean±s.d., baseline: n¼12 (I), n¼16 (C); week 3:
n¼13 (I) and n¼17 (C); week5: n¼8 (I), n¼13 (C). *Po0.05,
difference between the I and C group (analysed by generalised
estimating equations, with baseline value and sex as covariate).
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supplements.
To our knowledge, no other studies reported beneﬁcial effects
of n-3 FAs on quality of life in cancer during multimodality
treatment. In the current study, observed effects on quality of life
variables amounted 10--20 points on a 0--100 scale, indicating
clinical signiﬁcant improvements.
40 Because of the uneven
distribution of sex in the I and C groups, these differences might
be partly caused by sex, for example, when men are known to be
less critical towards their physical status than women. However,
after correcting for sex, the I group showed a statistically
signiﬁcant higher physical function and cognitive function than
the C group, and tendencies towards a higher global health status
and social function.
The physical function score expresses the capacity to perform
normal daily activities, such as to carry a heavy bag, to be able to
go for a walk, to be bedridden during daytime and to be
dependent on help with washing, dressing or eating. The I group
also showed a substantially better cognitive function, expressed
by reported concentration (for example, when watching television
or reading a newspaper) and memory capacity. Polyunsaturated
FAs are of importance in human brain development and n-3 FA
status might inﬂuence cognitive function. A number of studies
showed positive effects of docosahexaenoic acid supplementation
on cognitive function in Alzheimer disease, elderly and children.
Mechanistically, these phenomena have been explained by the
anti-inﬂammatory action of docosahexaenoic acid.
36 Further on,
reported problems with family life or social activities in the group
receiving n-3 FAs were substantially lower during chemoradiother-
apy. The intervention group also reported less nausea/vomiting
and ﬁnancial problems. These subjective ﬁndings are unlikely
caused by n-3 FAs and may be caused by selection bias or by
chance.
Physical activity is an important indicator of quality of life and
performance status in patients with cancer.
37,38 Gibney et al.
39
showed a reduced physical activity level in a small group of
patients with small cell lung cancer. Beneﬁcial effects of n-3 FAs
on physical activity level have been shown in one small
randomised controlled trial in pancreatic cancer patients.
16 In line
with the literature, we also found a reduced physical activity in
patients with stage III NSCLC. After 5 weeks of chemoradiotherapy,
physical activity in the group receiving the oral nutritional
supplement containing n-3 FAs increased, whereas physical
activity in the C group remained the same.
Although the statistical power of this study is limited, this is the
ﬁrst randomised controlled clinical trial indicating effects on both
objective and subjective functional and quality of life parameters.
n-3 Polyunsaturated FAs may beneﬁcially affect quality of life and
functional status in patients with NSCLC undergoing multimod-
ality treatment. Yet, more research is required to conﬁrm these
ﬁndings and to investigate the dose-response effect of n-3 FAs
during cancer treatment.
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